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Moving to African Americans*Paolo Verdecchia, MD,y Fabio Angeli, MD,z Gianpaolo Reboldi, MD, PHD, MSCxM asked hypertension (MH) reﬂects the falseimpression that because patients’ bloodpressure (BP) is <140/90 mm Hg in the
ofﬁce, their BP is either normal (if they are untreated)
or well controlled (if they are treated), although their
average BP levels are abnormally elevated out of the
ofﬁce, using either home BP or 24-h ambulatory BP
monitoring (1–4).SEE PAGE 2159In this issue of the Journal, Tientcheu et al. (5)
present an analysis of the DHS (Dallas Heart Study),
a population study designed to investigate ethnic
differences in cardiovascular health at the commu-
nity level (6). About 54% of subjects enrolled in this
study were African Americans (6). In this analysis, the
investigators compared subjects with ofﬁce normo-
tension, white-coat hypertension (WCH), MH, and
sustained hypertension on some indexes of organ
damage and cardiovascular outcome. Groups were
deﬁned on the basis of BP measured in the ofﬁce and
at home, not with 24-h ambulatory BP monitoring.
Evaluation criteria included some markers of arterial
stiffness and proteinuria and, more notably, the risk
for major cardiovascular events over a 9-year follow-
up period (5).
Over the past 20 years, several studies have shown
measurements of BP outside the ofﬁce to be superior to
measurements of BP in the ofﬁce in predicting target
organ damage and the risk for major cardiovascular*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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sity of Perugia, Perugia, Italy. The authors have reported that they have
no relationships relevant to the contents of this paper to disclose.events (7,8). The novelty of the present study stems
from the surprising paucity of data on the prognostic
impact of clinical phenotypes of out-of-ofﬁce BP,
particularly of MH and WCH, in African Americans.
However, it is well known that African Americans are
at increased risk for hypertensive organ damage and
cardiovascular complications (9).
The issue of MH (i.e., elevated BP outside the ofﬁce
in patients with normal BP in the ofﬁce) continues to
be challenging and intriguing. Some comprehensive
reviews (1–3,10) have shown that the prevalence of
MH varies between 8% and 50%, probably depending
on differences across studies in several important
factors, including baseline ofﬁce BP, antihypertensive
treatment, age, prevalence of smoking, and other
demographic features (2,3,10). For both MH and WCH,
the deﬁnition is more properly applied to untreated
patients (3,8). The apparent impression of controlled
(in MH) or uncontrolled (in WCH) ofﬁce BP in treated
patients may be explained not only by a different
alerting reaction to the ofﬁce visit but also by a dif-
ferential drop in ofﬁce versus out-of-ofﬁce BP,
possibly related to the timing of drug administration,
the duration of the antihypertensive effect, and other
reasons (8).
In the present study, Tientcheu et al. (5) found a
17.8% prevalence of MH and a 3.3% prevalence of
WCH in the total sample (13.6% and 2.2%, respec-
tively, in the untreated sample). In untreated pa-
tients, aortic pulsed wave velocity and the ratio of
urinary albumin to creatinine were signiﬁcantly
higher in the WCH and MH groups, and differences
remained signiﬁcant after multivariate adjustment
for some potential confounders. Conversely, some
of the differences between the groups did not
achieve signiﬁcance in treated patients. The risk
for cardiovascular events (a composite pool of 194
hard and less hard events, including unstable
angina, transient ischemic attack, revascularization,
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2171myocardial infarction, stroke, hospitalization for
atrial ﬁbrillation and heart failure, and cardiovascular
death) was assessed over a median 9-year follow-up
period. After adjustment for several potential con-
founders, the risk for events was signiﬁcantly higher
in the MH and sustained hypertension groups
compared with the normotensive group, whereas it
barely approached signiﬁcance (adjusted hazard
ratio: 2.02; 95% conﬁdence interval: 1.01 to 4.03) in
the WCH group.
Interestingly, a subgroup analysis showed almost
the same risk for events in the normotensive group
and in the WCH group among nonblacks, whereas a
signiﬁcantly higher risk for events was found in the
WCH group compared with the normotensive group
in blacks. The p test for interaction was not statisti-
cally signiﬁcant, but the analysis was probably un-
derpowered to test the signiﬁcance of such an
interaction. These ﬁndings support the hypothesis
that the prognostic impact of WCH differs in blacks
versus nonblacks, an intriguing hypothesis that
merits testing in future studies.
Some limitations of the present study must be
acknowledged when interpreting its results. First,
the deﬁnition of groups is on the basis of home BP,
not 24-h ambulatory BP. An obvious advantage of
24-h ambulatory BP over home BP is the ability of
24-h ambulatory BP to capture not only nocturnal
MH but also transient or persistent BP elevations out
of the home setting, possibly triggered by physical
and emotional stress. In a study from Spain, 31% of
4,608 treated hypertensive patients with ofﬁce
BP <140/90 mm Hg showed MH due to isolated in-
creases of nighttime BP in 27.3% (ﬁrst session) and
28.7% (second session) of patients (11). While waiting
for outcome-based studies on the prognostic impact
of MH using different time windows, 24-h ambulatory
BP monitoring should be theoretically preferred to
home BP recording in those subjects in whom MH is
suspected (10).
A second limitation of the study by Tientcheu et al.
(5) is inherent in the schedule of home and ofﬁce BP
measurements in the DHS. The ﬁrst data collection,
which included home BP measurement, occurred
during a single in-home visit carried out by health
care professionals. This is not exactly the same situ-
ation as several home BP readings by a patient in the
privacy of his or her home over different days and
times of day. According to an international consensus
document on home BP monitoring, home BP should
be monitored for 7 days, with at least 2 morning and 2
evening measurements. For clinical decision making,
we should consider the average of all values, except
for the ﬁrst day, which should be discarded (12). Somestress-induced overestimation of home BP might
have occurred in this study. However, the prevalence
of MH was unlikely to be inﬂated, as it was compa-
rable with that observed in the Jackson Heart Study, a
study conducted in African Americans that used 24-h
ambulatory BP monitoring (13).
A ﬁnal limitation relates to the temporal separation
between the visits. Some weeks after the ﬁrst data
collection, there was a second in-home visit that
included a blood drawing for biochemical analyses.
After several weeks, a third clinical visit was carried
out in the hospital, during which traditional ofﬁce BP
was measured. It is unknown whether drug treatment
changed between the ﬁrst and the third visits, and
this is, perhaps, the more serious potential limitation
of the present study. However, one might expect that
treatment did not change in most patients, because
community-based screening programs show negli-
gible changes in drug treatment due solely to the
effect of screening visits (14–16).
The present study has several strengths. Most
notably, for the ﬁrst time, the evidence that MH is
associated with an excess risk for organ damage and
major cardiovascular events is extended to a multi-
ethnic population with a high prevalence of African
Americans, thus extending the current database on
the adverse prognostic impact of MH. A meta-analysis
from our group showed a 2-fold higher risk for car-
diovascular events in patients with MH than in fully
normotensive subjects, regardless of the use of home
BP or 24-h ambulatory BP (16).
From a practical standpoint, we have no evidence
from controlled trials that patients with MH should be
treated, or treated more aggressively to further lower
their BP outside the ofﬁce. The European Society of
Cardiology and European Society of Hypertension
guidelines suggest that life-style measures and anti-
hypertensive drug treatment “should be considered”
in patients with MH because “this type of hyperten-
sion has been consistently found to have a cardio-
vascular risk very close to that of in- and out-of-ofﬁce
hypertension” (17). The guidelines made the same
recommendation for untreated and treated patients
with MH, and this is a Class IIA, Level of Evidence: C
recommendation (17). Randomized intervention
studies should be undertaken to compare different BP
targets outside the ofﬁce, regardless of BP measured
in the ofﬁce, in multiethnic populations of patients
with MH.
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